BENITIONSClinical Trial Intelligence

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

Фаза 4 Завершено NCT03061006

ЗаболеваниеDementia, Cognition Disorders, Cerebral Ischemic Events
ФазаФаза 4
СпонсорIntermountain Health Care, Inc.
СтатусЗавершено
Участники101 участн.
ВмешательствоDabigatran Etexilate, Warfarin
Дата начала30.03.2017
Дата завершения15.03.2021
Публикация результатов12.05.2026

Кратко

Patients will be screened at Intermountain Medical Center and at Intermountain-affiliated anticoagulation clinics in the Salt Lake City region. Patients with non-valvular atrial fibrillation will be considered for study. After written informed consent is obtained, subjects who meet eligibility criteria will be randomized 1:1 to 2 treatment arms: Group 1: Dabigatran etexilate (150 mg BID if CrCL \> 30 mL/min, or 75 mg BID if CrCL \> 15 to 30 mL/min or per USPI; and Group 2: Warfarin (Dose-adjusted (INR 2.0 - 3.0). Assessment of kidney function every 6 months will be done for Group 1. Standard warfarin follow-up and education, based upon system criteria, will be done for Group 2. All subjects will be followed for 24 months, and will be assessed at 1-week, then 3-, 6-, 12-, 18- and 24-months post-anticoagulation visits as well as other visits deem necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit following the week 1 visit, except at the 3-month visit when only one questionnaire will be administered. To determine brain volume and characteristic changes representative

Number of Participants With Incident Dementia Determined by a Formal Diagnosis of Dementia by a Neurologist

24 months · Participants

Dabigatran Etexilate0 Participants
Warfarin0 Participants

Number of Participants With Moderate Decline in Cognitive Function Based on Results of the Alzheimer's Disease Assessment Scale and the Disability Assessment for Dementia.

24 months · Participants

Dabigatran Etexilate5 Participants
Warfarin2 Participants
p-value0.23

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.